E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
High Risk Chronic Lymphocytic Leukemia |
Leucémie Lymphoïde Chronique à haut risque |
|
E.1.1.1 | Medical condition in easily understood language |
High Risk Chronic Lymphocytic Leukemia |
|
E.1.1.2 | Therapeutic area | Diseases [C] - Cancer [C04] |
MedDRA Classification |
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 19.0 |
E.1.2 | Level | LLT |
E.1.2 | Classification code | 10008976 |
E.1.2 | Term | Chronic lymphocytic leukemia |
E.1.2 | System Organ Class | 100000004864 |
|
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
To check the efficacy of acalabrutinib in subjects with relapsed/refractory CLL who are intolerant of ibrutinib therapy |
Évaluer l'efficacité de l'acalabrutinib chez des patients atteints de LLC en rechute ou réfractaire présentant une intolérance au traitement par ibrutinib. |
|
E.2.2 | Secondary objectives of the trial |
To evaluate the safety and tolerability of acalabrutinib in subjects with relapsed/refractory CLL who are intolerant of ibrutinib therapy EXPLORATORY OBJECTIVES: - To determine the effect of acalabrutinib on peripheral blood B cells, T cells, NK cells, and MDSCs. - To evaluate potential predictive biomarkers and mechanisms of resistance for the disease. |
Évalue la sécurité et la tolérance de l'acalabrutinib chez des patients atteints de LLC en rechute ou réfractaire présentant une intolérance au traitement par ibrutinib. Objectifs exploratoires : - Déterminer l'effet de l'acalabrutinib sur les lymphocytes B, les lymphocytes T, les lymphocytes NK et les lymphocytes suppresseurs d'origine myéloïde (MDSC) du sang périphérique. - Évaluer les biomarqueurs prédictifs potentiels et les mécanismes de résistance de la maladie.
|
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
1-Prior diagnosis of CLL that meets published diagnostic criteria (Hallek 2008) 2-Must have received ≥ 1 prior therapy for CLL and not be appropriate for treatment or retreatment with purine analogue-based therapy 3-Intolerant of ibrutinib, defined as the subject has discontinued ibrutinib therapy due to Grade 3 or 4 AEs that persisted in spite of optimal supportive care measures OR patients who had Grade 2 AEs related to ibrutinib therapy, in spite of optimal supportive care measures, that persisted for ≥ 2 weeks or that recurred ≥ 2 times whether dose was reduced or discontinued. 4-ECOG performance status of ≤ 2 |
|
E.4 | Principal exclusion criteria |
1-Ongoing Grade 3 or 4 AE attributed to ibrutinib therapy. Note: Patients may be eligible for enrollment once the ibrutinib-related AE improves to Grade ≤ 2. 2-Treatment with systemic anticancer therapy for CLL is prohibited between discontinuation of ibrutinib and enrollment on this trial. 3-Prior exposure to a BCL-2 inhibitor (eg, ABT-199). 4-Prior malignancy (other than CLL), except for adequately treated basal cell or squamous cell skin cancer, in situ cancer, or other cancer from which the subject has been disease free for ≥ 2 years. |
|
E.5 End points |
E.5.1 | Primary end point(s) |
Efficacy will be evaluated based on the IWCLL 2008 criteria. The primary efficacy endpoint is Overall Response Rate (ORR) assessed by the investigators at the end of treatment. |
|
E.5.1.1 | Timepoint(s) of evaluation of this end point |
|
E.5.2 | Secondary end point(s) |
The secondary efficacy endpoints are: - Duration of Response (DOR) - Progression-Free Survival (PFS) - Time to Next Treatment (TTNT) - Overall Survival (OS)
The safety of acalabrutinib will be characterized by laboratory assessments performed throughout the study and the type, frequency, severity, and attribution of AEs, or AEs leading to discontinuation of study treatment.
The exploratory objectives will be evaluated through pharmacodynamic and biomarker parameters. The occupancy of Btk by acalabrutinib will be measured in PBMCs with the aid of a biotin-tagged acalabrutinib analogue probe. The effect of acalabrutinib on B cells, NK cells (CD56+), T cells (CD3+, CD4+, CD8+ levels), and MDSCs (HLA-DR- CD14+CD11b+ CD33+ levels) will also be evaluated. Genotyping for Btk, p53, and PLC? mutations will be performed. |
|
E.5.2.1 | Timepoint(s) of evaluation of this end point |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | No |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | No |
E.6.7 | Pharmacodynamic | Yes |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | Yes |
E.7.3 | Therapeutic confirmatory (Phase III) | No |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | No |
E.8.1.1 | Randomised | No |
E.8.1.2 | Open | Yes |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | No |
E.8.1.5 | Parallel group | No |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | No |
E.8.2.2 | Placebo | No |
E.8.2.3 | Other | No |
E.8.3 |
The trial involves single site in the Member State concerned
| No |
E.8.4 | The trial involves multiple sites in the Member State concerned | Yes |
E.8.4.1 | Number of sites anticipated in Member State concerned | 6 |
E.8.5 | The trial involves multiple Member States | Yes |
E.8.5.1 | Number of sites anticipated in the EEA | 15 |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | Yes |
E.8.6.2 | Trial being conducted completely outside of the EEA | No |
E.8.6.3 | If E.8.6.1 or E.8.6.2 are Yes, specify the regions in which trial sites are planned |
Belgium |
France |
Israel |
Spain |
United Kingdom |
United States |
|
E.8.7 | Trial has a data monitoring committee | No |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
The end of trial is defined as the point when the last subject enrolled completes end of Cycle 36 or withdraws for any reason and completes the 30-day SFU visit (if applicable), whichever occurs first. |
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 3 |
E.8.9.1 | In the Member State concerned months | 8 |
E.8.9.1 | In the Member State concerned days | 0 |
E.8.9.2 | In all countries concerned by the trial years | 3 |
E.8.9.2 | In all countries concerned by the trial months | 8 |
E.8.9.2 | In all countries concerned by the trial days | 0 |